http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101536050-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101536050-B1 |
| titleOfInvention | Novel Isatin-Based Hydroxamic Acids and Anti-Cancer Composition Comprising the Same As Active Ingredient |
| abstract | The present invention relates to novel isatin-based hydroxamic acid and an anticancer composition comprising the same as an active ingredient. The hydroxamic acid compound of the present invention has an inhibitory activity against histone deacetylase (HDAC), exhibits cytotoxicity in various cancer cells and exhibits anticancer efficacy, and thus can be developed as an active ingredient of a potent anticancer drug. |
| priorityDate | 2013-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 291.